<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d569">
    <sentence id="DDI-DrugBank.d569.s0" text="Angiomax does not exhibit binding to plasma proteins (other than thrombin) or red blood cells.">
        <entity id="DDI-DrugBank.d569.s0.e0" charOffset="0-7"
            type="brand" text="Angiomax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s1" text="In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.">
        <entity id="DDI-DrugBank.d569.s1.e0" charOffset="73-80"
            type="brand" text="Angiomax"/>
        <entity id="DDI-DrugBank.d569.s1.e1" charOffset="87-93"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d569.s1.e2" charOffset="96-103"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d569.s1.e3" charOffset="106-118"
            type="group" text="thrombolytics"/>
        <pair id="DDI-DrugBank.d569.s1.p0" e1="DDI-DrugBank.d569.s1.e0"
            e2="DDI-DrugBank.d569.s1.e1" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d569.s1.p1" e1="DDI-DrugBank.d569.s1.e0"
            e2="DDI-DrugBank.d569.s1.e2" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d569.s1.p2" e1="DDI-DrugBank.d569.s1.e0"
            e2="DDI-DrugBank.d569.s1.e3" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d569.s1.p3" e1="DDI-DrugBank.d569.s1.e1"
            e2="DDI-DrugBank.d569.s1.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d569.s1.p4" e1="DDI-DrugBank.d569.s1.e1"
            e2="DDI-DrugBank.d569.s1.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d569.s1.p5" e1="DDI-DrugBank.d569.s1.e2"
            e2="DDI-DrugBank.d569.s1.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s2" text="There is no experience with co-administration of Angiomax and plasma expanders such as dextran.">
        <entity id="DDI-DrugBank.d569.s2.e0" charOffset="49-56"
            type="brand" text="Angiomax"/>
        <entity id="DDI-DrugBank.d569.s2.e1" charOffset="87-93"
            type="drug" text="dextran"/>
        <pair id="DDI-DrugBank.d569.s2.p0" e1="DDI-DrugBank.d569.s2.e0"
            e2="DDI-DrugBank.d569.s2.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s3" text="Angiomax should be used with caution in patients with disease states associated with an increased risk of bleeding.">
        <entity id="DDI-DrugBank.d569.s3.e0" charOffset="0-7"
            type="brand" text="Angiomax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s4" text="Immunogenicity/Re-exposure: In in vitro studies, Angiomax exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.">
        <entity id="DDI-DrugBank.d569.s4.e0" charOffset="49-56"
            type="brand" text="Angiomax"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s5" text="Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.">
        <entity id="DDI-DrugBank.d569.s5.e0" charOffset="32-39"
            type="brand" text="Angiomax"/>
        <entity id="DDI-DrugBank.d569.s5.e1" charOffset="135-145"
            type="drug" text="bivalirudin"/>
        <pair id="DDI-DrugBank.d569.s5.p0" e1="DDI-DrugBank.d569.s5.e0"
            e2="DDI-DrugBank.d569.s5.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d569.s6" text="Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed."/>
    <sentence id="DDI-DrugBank.d569.s7" text="Nine additional patients who had initial positive tests were negative on repeat testing."/>
</document>
